Entrada Therapeutics, Inc. Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Entrada Therapeutics, Inc. has an operating margin of 22.3%, meaning the company retains $22 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from -2.5% the prior year.
Entrada Therapeutics, Inc.'s revenue surged 63.4% year-over-year to $210.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Entrada Therapeutics, Inc. carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 11.15, Entrada Therapeutics, Inc. holds $11.15 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Entrada Therapeutics, Inc. generated -$41.6M in operating cash flow, capex of $3.2M consumed most of it, leaving -$44.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Entrada Therapeutics, Inc.'s ROE of 15.3% shows moderate profitability relative to equity, earning a score of 61/100.
Entrada Therapeutics, Inc. scores 3.82, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($415.8M) relative to total liabilities ($97.6M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Entrada Therapeutics, Inc. passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Entrada Therapeutics, Inc. generates $-0.63 in operating cash flow (-$41.6M OCF vs $65.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Entrada Therapeutics, Inc. (TRDA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Entrada Therapeutics, Inc. generated $210.8M in revenue in fiscal year 2024. This represents an increase of 63.4% from the prior year.
Entrada Therapeutics, Inc.'s EBITDA was $50.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15920.6% from the prior year.
Entrada Therapeutics, Inc. generated -$44.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 133.3% from the prior year.
Entrada Therapeutics, Inc. reported $65.6M in net income in fiscal year 2024. This represents an increase of 1081.7% from the prior year.
Entrada Therapeutics, Inc. earned $1.68 per diluted share (EPS) in fiscal year 2024. This represents an increase of 940.0% from the prior year.
Entrada Therapeutics, Inc. held $101.2M in cash against $0 in long-term debt as of fiscal year 2024.
Entrada Therapeutics, Inc. had 38M shares outstanding in fiscal year 2024. This represents an increase of 12.4% from the prior year.
Entrada Therapeutics, Inc.'s operating margin was 22.3% in fiscal year 2024, reflecting core business profitability. This is up 24.8 percentage points from the prior year.
Entrada Therapeutics, Inc.'s net profit margin was 31.1% in fiscal year 2024, showing the share of revenue converted to profit. This is up 36.3 percentage points from the prior year.
Entrada Therapeutics, Inc.'s ROE was 15.3% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.
Entrada Therapeutics, Inc. invested $125.3M in research and development in fiscal year 2024. This represents an increase of 25.5% from the prior year.
Entrada Therapeutics, Inc. invested $3.2M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 43.7% from the prior year.
TRDA Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M-17.2% | $1.9M-90.5% | $20.6M-45.0% | $37.4M-60.5% | $94.7M+60.2% | $59.1M+41.3% | $41.8M-4.3% | $43.7M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $38.4M+1.3% | $37.9M+18.1% | $32.1M-4.0% | $33.4M+4.3% | $32.0M+12.0% | $28.6M+1.1% | $28.3M+27.5% | $22.2M |
| SG&A Expenses | $10.3M-5.7% | $10.9M+6.3% | $10.3M+4.2% | $9.9M+6.7% | $9.2M-1.7% | $9.4M+8.6% | $8.7M+14.9% | $7.5M |
| Operating Income | -$47.1M-0.4% | -$46.8M-115.0% | -$21.8M-271.4% | -$5.9M-111.0% | $53.4M+153.0% | $21.1M+330.4% | $4.9M-65.0% | $14.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $654K+267.4% | $178K | $0+100.0% | -$1.9M-167.8% | $2.8M+50.6% | $1.8M-90.2% | $18.7M+207.7% | -$17.4M |
| Net Income | -$44.1M-2.4% | -$43.1M-148.4% | -$17.3M-1634.0% | $1.1M-97.9% | $55.0M+134.2% | $23.5M+346.2% | -$9.5M-126.9% | $35.5M |
| EPS (Diluted) | $-1.06-1.9% | $-1.04-147.6% | $-0.42-110.0% | $-0.20-112.9% | $1.55+127.9% | $0.68+395.7% | $-0.23-122.5% | $1.02 |
TRDA Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $412.9M-8.0% | $448.8M-7.7% | $486.5M-7.6% | $526.3M-9.6% | $582.0M+13.9% | $510.8M+8.9% | $469.2M-3.3% | $485.0M |
| Current Assets | $338.3M-8.4% | $369.1M-8.4% | $403.2M-8.4% | $440.0M-10.1% | $489.5M+18.2% | $414.2M+12.0% | $369.8M-3.5% | $383.0M |
| Cash & Equivalents | $93.3M+28.7% | $72.5M+6.8% | $67.8M-33.0% | $101.2M-45.4% | $185.3M+170.7% | $68.4M+1.2% | $67.6M+30.3% | $51.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $72.2M+4.2% | $69.3M+0.1% | $69.2M-29.1% | $97.6M-35.8% | $152.0M-37.0% | $241.5M+6.5% | $226.8M-4.8% | $238.4M |
| Current Liabilities | $24.0M+21.3% | $19.8M+7.4% | $18.4M-53.3% | $39.5M-54.0% | $85.8M-50.7% | $173.9M+9.5% | $158.8M-4.0% | $165.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $340.7M-10.2% | $379.5M-9.0% | $417.3M-2.7% | $428.7M-0.3% | $429.9M+59.6% | $269.4M+11.1% | $242.4M-1.7% | $246.7M |
| Retained Earnings | -$233.9M-23.3% | -$189.8M-29.4% | -$146.7M-13.4% | -$129.3M-11.1% | -$116.4M+32.1% | -$171.5M+12.1% | -$195.0M-5.1% | -$185.4M |
TRDA Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$28.3M+4.0% | -$29.5M+23.4% | -$38.5M-21.8% | -$31.6M-179.3% | $39.8M+256.1% | -$25.5M-535.9% | -$4.0M+83.6% | -$24.5M |
| Capital Expenditures | -$171K-162.2% | $275K-76.0% | $1.1M+80.2% | $635K-39.3% | $1.0M+24.8% | $838K-14.1% | $976K-32.6% | $1.4M |
| Free Cash Flow | -$28.5M+4.3% | -$29.8M+24.9% | -$39.7M-23.0% | -$32.2M-183.1% | $38.8M+247.2% | -$26.4M-428.3% | -$5.0M+80.8% | -$25.9M |
| Investing Cash Flow | $49.1M+45.3% | $33.8M+606.6% | $4.8M-91.0% | $53.4M+318.9% | -$24.4M-193.3% | $26.1M+37.3% | $19.0M+609.6% | -$3.7M |
| Financing Cash Flow | $8K-97.6% | $337K-3.7% | $350K-75.0% | $1.4M-98.6% | $101.4M+49107.3% | $206K-70.1% | $690K+87.5% | $368K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TRDA Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -2915.2%-512.7pp | -2402.5%-2296.5pp | -106.0%-90.3pp | -15.7%-72.1pp | 56.4%+20.7pp | 35.7%+24.0pp | 11.7%-20.3pp | 32.0% |
| Net Margin | -2734.4%-524.0pp | -2210.4%-2126.0pp | -84.4%-87.4pp | 3.0%-55.1pp | 58.1%+18.4pp | 39.7%+62.5pp | -22.8%-103.9pp | 81.1% |
| Return on Equity | N/A | N/A | N/A | 0.3%-12.5pp | 12.8%+4.1pp | 8.7% | N/A | 14.4% |
| Return on Assets | -10.7%-1.1pp | -9.6%-6.0pp | -3.6%-3.8pp | 0.2%-9.3pp | 9.5%+4.9pp | 4.6%+6.6pp | -2.0%-9.3pp | 7.3% |
| Current Ratio | 14.08-4.6 | 18.64-3.2 | 21.88+10.7 | 11.15+5.4 | 5.70+3.3 | 2.38+0.1 | 2.33+0.0 | 2.32 |
| Debt-to-Equity | 0.21+0.0 | 0.18+0.0 | 0.17-0.1 | 0.23-0.1 | 0.35-0.5 | 0.90-0.0 | 0.94-0.0 | 0.97 |
| FCF Margin | -1764.8%-238.4pp | -1526.4%-1333.5pp | -192.9%-106.7pp | -86.2%-127.2pp | 41.0%+85.5pp | -44.6%-32.7pp | -11.9%+47.4pp | -59.3% |
Similar Companies
Frequently Asked Questions
What is Entrada Therapeutics, Inc.'s annual revenue?
Entrada Therapeutics, Inc. (TRDA) reported $210.8M in total revenue for fiscal year 2024. This represents a 63.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Entrada Therapeutics, Inc.'s revenue growing?
Entrada Therapeutics, Inc. (TRDA) revenue grew by 63.4% year-over-year, from $129.0M to $210.8M in fiscal year 2024.
Is Entrada Therapeutics, Inc. profitable?
Yes, Entrada Therapeutics, Inc. (TRDA) reported a net income of $65.6M in fiscal year 2024, with a net profit margin of 31.1%.
What is Entrada Therapeutics, Inc.'s earnings per share (EPS)?
Entrada Therapeutics, Inc. (TRDA) reported diluted earnings per share of $1.68 for fiscal year 2024. This represents a 940.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Entrada Therapeutics, Inc.'s EBITDA?
Entrada Therapeutics, Inc. (TRDA) had EBITDA of $50.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Entrada Therapeutics, Inc.'s operating margin?
Entrada Therapeutics, Inc. (TRDA) had an operating margin of 22.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Entrada Therapeutics, Inc.'s net profit margin?
Entrada Therapeutics, Inc. (TRDA) had a net profit margin of 31.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Entrada Therapeutics, Inc.'s return on equity (ROE)?
Entrada Therapeutics, Inc. (TRDA) has a return on equity of 15.3% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Entrada Therapeutics, Inc.'s free cash flow?
Entrada Therapeutics, Inc. (TRDA) generated -$44.7M in free cash flow during fiscal year 2024. This represents a -133.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Entrada Therapeutics, Inc.'s operating cash flow?
Entrada Therapeutics, Inc. (TRDA) generated -$41.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Entrada Therapeutics, Inc.'s total assets?
Entrada Therapeutics, Inc. (TRDA) had $526.3M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Entrada Therapeutics, Inc.'s capital expenditures?
Entrada Therapeutics, Inc. (TRDA) invested $3.2M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Entrada Therapeutics, Inc. spend on research and development?
Entrada Therapeutics, Inc. (TRDA) invested $125.3M in research and development during fiscal year 2024.
How many shares does Entrada Therapeutics, Inc. have outstanding?
Entrada Therapeutics, Inc. (TRDA) had 38M shares outstanding as of fiscal year 2024.
What is Entrada Therapeutics, Inc.'s current ratio?
Entrada Therapeutics, Inc. (TRDA) had a current ratio of 11.15 as of fiscal year 2024, which is generally considered healthy.
What is Entrada Therapeutics, Inc.'s debt-to-equity ratio?
Entrada Therapeutics, Inc. (TRDA) had a debt-to-equity ratio of 0.23 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Entrada Therapeutics, Inc.'s return on assets (ROA)?
Entrada Therapeutics, Inc. (TRDA) had a return on assets of 12.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Entrada Therapeutics, Inc.'s cash runway?
Based on fiscal year 2024 data, Entrada Therapeutics, Inc. (TRDA) had $101.2M in cash against an annual operating cash burn of $41.6M. This gives an estimated cash runway of approximately 29 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Entrada Therapeutics, Inc.'s Altman Z-Score?
Entrada Therapeutics, Inc. (TRDA) has an Altman Z-Score of 3.82, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Entrada Therapeutics, Inc.'s Piotroski F-Score?
Entrada Therapeutics, Inc. (TRDA) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Entrada Therapeutics, Inc.'s earnings high quality?
Entrada Therapeutics, Inc. (TRDA) has an earnings quality ratio of -0.63x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Entrada Therapeutics, Inc.?
Entrada Therapeutics, Inc. (TRDA) scores 77 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.